Changes in Plasma Clearance of CYP450 Probe Drugs May Not be Specific for Altered In Vivo Enzyme Activity Under (Patho)Physiological Conditions: How to Interpret Findings of Probe Cocktail Studies
As plasma protein binding can change under (patho)physiological conditions, alterations in unbound drug fraction should be accounted for when using CYP probe drug plasma clearance as a proxy for CYP enzyme activity in patient populations. The tool developed in this study can support researchers in determining alterations in CYP enzyme activity in patients with (patho)physiological conditions.
Authors
- Catherijne A. J. Knibbe (ORCID: https://orcid.org/0000-0001-9893-4415)
- Elke H. J. Krekels (ORCID: https://orcid.org/0000-0001-6006-1567)
- J. G. Coen van Hasselt (ORCID: https://orcid.org/0000-0002-1664-7314)
- Laura M. de Jong (ORCID: https://orcid.org/0000-0001-9719-6051)
- Jesse J. Swen (ORCID: https://orcid.org/0000-0002-3965-5552)
- Mitra Ahmadi (ORCID: https://orcid.org/0000-0003-0139-6302)
- Martijn L. Manson (ORCID: https://orcid.org/0000-0002-5508-8615)
- Marinda van de Kreeke (ORCID: https://orcid.org/0000-0001-9904-131X)
Institutions
- Princeton University (US)
- Leiden University Medical Center (NL)
- St. Antonius Ziekenhuis (NL)
- Certara (United States) (US)
- Centre for Human Drug Research (NL)
- Integra LifeSciences (United States) (US)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2024-10-27
- DOI
- https://doi.org/10.1007/s40262-024-01426-8
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00